
  
    
      
        
        In_IN a_DT compelling_JJ essay_NN in_IN this_DT issue_NN of_IN 
        PLoS_NNP Medicine_NNP ,_, Mike_NNP Clarke_NNP ,_, the_DT director_NN of_IN the_DT United_NNP Kingdom_NNP Cochrane_NNP
        Centre_NNP ,_, lays_VBZ down_RP a_DT challenge_NN to_TO clinical_JJ researchers_NNS and_CC journal_NN editors_NNS [_NN 1_CD ]_NN ._. He_PRP argues_VBZ
        that_IN researchers_NNS should_MD do_VB a_DT study_NN only_RB if_IN there_EX is_VBZ a_DT systematic_JJ review_NN that_WDT shows_VBZ that_IN the_DT
        new_JJ study_NN is_VBZ needed_VBN ._. If_IN no_DT review_NN exists_VBZ ,_, the_DT researchers_NNS should_MD do_VB one_CD themselves_PRP before_IN
        embarking_VBG on_IN their_PRP$ research_NN ._. And_CC journals_NNS ,_, he_PRP argues_VBZ ,_, should_MD publish_VB a_DT study_NN only_RB if_IN an_DT
        updated_VBN systematic_JJ review_NN is_VBZ incorporated_VBN into_IN the_DT study_NN ,_, or_CC published_VBD alongside_IN it_PRP or_CC
        shortly_RB thereafter_RB ._. How_WRB should_MD editors_NNS respond_VB to_TO his_PRP$ challenge_NN ?_.
        First_LS ,_, we_PRP would_MD argue_VB that_IN by_IN the_DT time_NN a_DT paper_NN is_VBZ sent_VBN to_TO a_DT journal_NN ,_, it_PRP is_VBZ surely_RB too_RB
        late_RB in_IN the_DT process_NN to_TO be_VB insisting_VBG on_IN systematic_JJ reviews_NNS ._. If_IN a_DT clinical_JJ trial_NN report_NN meets_VBZ
        our_PRP$ criteria_NNS for_IN originality_NN ,_, importance_NN ,_, and_CC quality_NN ,_, it_PRP makes_VBZ little_JJ sense_NN for_IN us_PRP to_TO
        reject_VB it_PRP just_RB because_IN the_DT authors_NNS failed_VBD to_TO systematically_RB review_VB the_DT literature_NN when_WRB
        designing_VBG their_PRP$ study_NN ._. The_DT time_NN to_TO mandate_VB that_IN researchers_NNS do_VBP a_DT review_NN is_VBZ much_JJ
        earlier—when_NN they_PRP apply_VBP for_IN funding_NN ,_, register_VB their_PRP$ trial_NN ,_, or_CC seek_VB ethics_NNS committee_NN
        approval_NN ._.
        There_EX is_VBZ no_DT doubt_NN that_IN the_DT best_JJS research_NN builds_VBZ on_IN previous_JJ knowledge_NN ._. But_CC
        unfortunately_RB ,_, the_DT current_JJ medical_JJ publishing_VBG system_NN hides_NNS much_JJ of_IN this_DT knowledge_NN behind_IN
        subscription_NN or_CC “ pay_VB per_IN view_NN” charges_NNS ,_, which_WDT discriminates_NNS against_IN researchers_NNS who_WP do_VBP not_RB
        work_VB for_IN well-funded_JJ institutions_NNS ._. A_DT group_NN of_IN researchers_NNS in_IN Indonesia_NNP ,_, for_IN example_NN ,_,
        recently_RB told_VBD a_DT depressingly_RB familiar_JJ story_NN of_IN trying_VBG to_TO search_VB the_DT medical_JJ literature_NN in_IN
        preparation_NN for_IN a_DT research_NN project_NN [_NN 2_CD ]_NN ;_: access_NN barriers_NNS got_VBD in_IN their_PRP$ way_NN ._. So_RB our_PRP$ second_JJ
        response_NN to_TO Clarke_NNP 's_POS challenge_NN is_VBZ that_IN it_PRP will_MD remain_VB difficult_JJ for_IN researchers_NNS ,_,
        particularly_RB in_IN resource-poor_JJ settings_NNS ,_, to_TO do_VB systematic_JJ reviews_NNS unless_IN the_DT medical_JJ
        literature_NN is_VBZ made_VBN a_DT freely_RB available_JJ public_JJ resource_NN ._.
        Many_JJ clinical_JJ trials_NNS ,_, especially_RB negative_JJ ones_NNS ,_, remain_VB unpublished_JJ ,_, which_WDT prevents_VBZ
        researchers_NNS from_IN reviewing_VBG all_PDT the_DT data_NN on_IN an_DT important_JJ health_NN issue_NN ._. There_EX are_VBP two_CD main_JJ
        reasons_NNS why_WRB certain_JJ trials_NNS are_VBP not_RB published_VBN :_: one_CD is_VBZ that_IN the_DT pharmaceutical_JJ industry_NN has_VBZ a_DT
        long_JJ history_NN of_IN suppressing_VBG data_NNS that_WDT are_VBP commercially_RB unfavorable_JJ and_CC the_DT second_NN is_VBZ that_IN
        medical_JJ journals_NNS and_CC the_DT popular_JJ media_NNS favor_VBP publication_NN of_IN positive_JJ over_IN negative_JJ trials_NNS
        (_( after_IN all_DT ,_, negative_JJ trials_NNS do_VBP not_RB make_VB for_IN a_DT provocative_JJ newspaper_NN headline_NN )_) ._. While_IN we_PRP
        support_VBP the_DT recent_JJ announcement_NN on_IN trial_NN registration_NN by_IN the_DT International_NNP Committee_NNP of_IN
        Medical_NNP Journal_NNP Editors—as_NNP a_DT condition_NN of_IN considering_VBG a_DT trial_NN for_IN publication_NN ,_, member_NN
        journals_NNS will_MD require_VB registration_NN of_IN the_DT trial_NN in_IN a_DT public_JJ trials_NNS registry_NN [_NN 3_CD ]_NN —_NN we_PRP believe_VBP
        that_IN this_DT policy_NN addresses_NNS only_RB part_NN of_IN the_DT problem_NN ._.
        The_DT scientific_JJ literature_NN will_MD remain_VB biased_VBN unless_IN the_DT publishing_VBG industry_NN changes_VBZ its_PRP$
        practices_NNS and_CC provides_VBZ a_DT place_NN where_WRB the_DT results_NNS from_IN all_DT registered_VBN trials_NNS can_MD be_VB
        published_VBN ._. 
        PLoS_NNP Medicine_NNP is_VBZ committed_VBN to_TO publishing_NN high-quality_JJ negative_JJ trials_NNS ._. In_IN
        this_DT issue_NN ,_, for_IN example_NN ,_, we_PRP publish_VB an_DT important_JJ randomized_JJ controlled_VBN trial_NN of_IN a_DT malaria_NN
        vaccine_NN in_IN 372_CD Gambian_NNP men_NNS ,_, which_WDT found_VBD that_IN the_DT vaccine_NN was_VBD ineffective_JJ at_IN reducing_VBG the_DT
        natural_JJ infection_NN rate_NN ._.
        The_DT internet_NN makes_VBZ it_PRP possible_JJ for_IN every_DT single_JJ clinical_JJ trial_NN to_TO be_VB publicly_RB and_CC
        seamlessly_RB tracked_VBN through_IN three_CD tiers_NNS ._. The_DT first_JJ tier_NN is_VBZ registration_NN in_IN a_DT publicly_RB
        available_JJ database_NN ._. The_DT second_NN is_VBZ the_DT publication_NN of_IN a_DT peer-reviewed_JJ summary_NN of_IN every_DT
        trial_NN ,_, regardless_RB of_IN its_PRP$ outcome_NN ,_, in_IN a_DT traditional_JJ journal_NN format_NN ,_, with_IN annotations_NNS and_CC
        critiques_NNS that_WDT help_VBP readers_NNS understand_VB the_DT trial_NN 's_POS implications_NNS ._. The_DT third_NN is_VBZ the_DT
        deposition_NN of_IN detailed_JJ trial_NN data_NNS in_IN a_DT structured_VBN ,_, computable_JJ format_NN that_WDT allows_VBZ
        sophisticated_JJ searching_VBG and_CC analyses_NNS across_IN trials_NNS ._. This_DT format_NN will_MD allow_VB the_DT development_NN
        of_IN better_JJR tools_NNS to_TO help_VB clinicians_NNS apply_VB trial_NN results_NNS to_TO their_PRP$ practice_NN ._. For_IN trial_NN data_NNS to_TO
        be_VB as_RB useful_JJ as_IN possible_JJ ,_, all_DT three_CD tiers_NNS must_MD be_VB publicly_RB accessible_JJ ._. Assessment_NNP of_IN each_DT
        trial_NN 's_POS validity_NN is_VBZ critical_JJ ,_, but_CC should_MD not_RB stop_VB crucial_JJ information_NN about_IN all_DT trials_NNS
        being_VBG placed_VBN in_IN the_DT public_JJ domain_NN ._.
        Trial_NN registries_NNS exist_VBP ,_, such_JJ as_IN ClinicalTrials_NNP ._. gov_NN and_CC the_DT International_NNP Standard_NNP
        Randomised_NNP Controlled_NNP Trial_NNP Number_NNP registry_NN ._. Moreover_RB ,_, many_JJ trials_NNS are_VBP registered_VBN in_IN a_DT
        semi-public_JJ database_NN maintained_VBN by_IN the_DT United_NNP States_NNPS Food_NNP and_CC Drug_NNP Administration_NNP ,_, and_CC
        there_EX are_VBP compelling_JJ arguments_NNS (_( which_WDT Turner_NNP articulates_NNS in_IN an_DT essay_NN published_VBD online_NN ahead_RB
        of_IN our_PRP$ December_NNP issue_NN [_NN 4_CD ]_NN )_) for_IN making_VBG this_DT a_DT truly_RB public_JJ resource_NN ._. Publicly_RB accessible_JJ
        trial_NN databases_NNS (_( such_JJ as_IN the_DT Trial_NNP Bank_NNP Project_NNP at_IN http_NN :_: /_NN /_NN rctbank_NN ._. ucsf_NN ._. edu_NN )_) are_VBP under_IN
        development_NN ._. And_CC as_IN a_DT publisher_NN committed_VBN to_TO open_VB access_NN ,_, PLoS_NNP will_MD provide_VB the_DT second_JJ ,_,
        essential_JJ tier—journals_NNS capable_JJ of_IN peer_VBP reviewing_VBG and_CC publishing_VBG an_DT annotated_JJ report_NN of_IN
        every_DT trial_NN ._. Traditional_NNP medical_JJ journals_NNS ,_, with_IN their_PRP$ subscription-based_JJ model_NN ,_, are_VBP
        unlikely_JJ to_TO be_VB able_JJ to_TO provide_VB this_DT service_NN ,_, because_IN in_IN order_NN to_TO attract_VB subscribers_NNS they_PRP
        need_VBP to_TO publish_VB only_RB the_DT highest-profile_JJ trials_NNS ._. We_PRP believe_VBP that_IN an_DT open-access_JJ model—in_NN
        which_WDT the_DT research_NN funder_NN pays_VBZ a_DT publication_NN fee_NN to_TO recover_VB the_DT costs_NNS of_IN peer_VBP review_NN and_CC
        for_IN hosting_VBG the_DT report_NN on_IN a_DT secure_VB server—is_NNS the_DT best_JJS mechanism_NN for_IN creating_VBG such_JJ venues_NNS ._.
        We_PRP are_VBP working_VBG to_TO make_VB that_DT happen_VBP ._.
        Returning_NNP to_TO Clarke_NNP 's_POS challenge_NN ,_, our_PRP$ final_JJ response_NN is_VBZ to_TO say_VB that_IN we_PRP have_VBP a_DT bold_JJ vision_NN
        of_IN a_DT freely_RB accessible_JJ online_NN world_NN of_IN clinical_JJ trials—from_NN registration_NN to_TO annotated_JJ
        summaries_NNS to_TO trial_NN databases_NNS ._. That_DT world_NN would_MD be_VB even_RB richer_JJR if_IN every_DT systematic_JJ review_NN
        were_VBD made_VBN freely_RB available_JJ ._. We_PRP challenge_VBP the_DT Cochrane_NNP Collaboration_NNP to_TO put_VB the_DT full_JJ text_NN of_IN
        all_DT of_IN its_PRP$ reviews_NNS into_IN the_DT public_JJ domain_NN ._. We_PRP hope_VBP the_DT Cochrane_NNP Collaboration_NNP will_MD join_VB us_PRP
        in_IN the_DT open-access_JJ revolution_NN ._.
      
    
  
